尼莫图祖马布加同步化疗和放射治疗为局部晚期宫平细胞癌 (NOTABLE-306) 的连续维持治疗:多中心,前性,随机化,双盲,安慰剂受控试验
Shuhua Wei1, Xiaofan Li2, Zi Liu3
1Department of Radiation Oncology, Peking University Third Hospital, Beijing, China.
Journal of gynecologic oncology
|January 9, 2026
概括
这项研究研究了尼莫图祖马布与晚期子宫癌的化疗放射治疗的结合. 添加尼莫图祖马布旨在改善患有局部晚期宫支状癌的患者的无进展生存率.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 辐射瘤学 辐射瘤学
背景情况:
- 基于西斯普拉丁的并发化疗放射治疗 (CCRT) 是局部晚期子宫癌的标准.
- 表皮生长因子受体 (EGFR) 的过度表达与对CCRT的反应不佳有关.
- 向EGFR是一种改善宫癌治疗结果的潜在策略.
研究的目的:
- 评估尼莫图祖马布加CCRT与单独CCRT的疗效和安全性.
- 评估尼莫图祖马布能否改善局部晚期宫状瘤的无进展生存期 (PFS).
主要方法:
- 第Ib/III期随机,双盲,安慰剂控制的NOTABLE-306试验 (NCT06333821) 进行了测试.
- Ib期:剂量升级以找到最佳的尼莫图祖马布剂量.
- 第三阶段:随机分配给尼莫图祖马布或安慰剂的患者,并进行CCRT (放射治疗+每周服用西斯) 和胸膜治疗. 主要终点:PFS.
主要成果:
- 第三阶段的主要终点是无进展生存期 (PFS).
- 二级终点将包括整体生存率,客观反应率和安全性.
- 结果正在等待患者招募和随访的完成.
结论:
- 尼莫图祖马布通过向EGFR,可以增强局部晚期宫癌中CCRT的疗效.
- 该NOTABLE-306试验将提供关键数据关于尼莫图祖马布在改善PFS中的作用.
- 预计到2030年4月将获得进一步的结果.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.8K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
594
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
594
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
564
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
564